This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study hypothesizes that C31G and Conceptrol vaginal gels will be comparable in contraceptive efficacy and safety. The primary objective is contraceptive efficacy; the secondary, acceptability, safety, incidence of UTI/vaginitis, colposcopic lesions in a non-NYU subset of subjects, changes in vaginal microflora. These outcomes will be assessed over six months. The study design is a multicenter, randomized, double-blind, phase III. Development of a spermicide with broad-spectrum antibiotic and anti-retroviral activity would be a significant advance.
Showing the most recent 10 out of 470 publications